CRANFORD, N.J., June 29, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on developing and
commercializing critical care drug products, announced today that
its CEO, Myron Holubiak, is
scheduled to appear as a featured guest on TD Ameritrade Network's
The Watch List with host Nicole
Petallides on Tuesday, June 30,
2020 at 1:20pm ET. Interested
parties may view the live interview at
https://tdameritradenetwork.com/.
The Watch List, hosted by with Nicole Petallides, highlights a panel of experts
ranging from industry-leading CEOs, analysts, and Wall Street
influencers to discuss pressing topics moving the market and is
intended to provide viewers with a status update for the end of the
trading day and beyond.
Mr. Holubiak has extensive experience in managing and leading
both large and emerging pharmaceutical and life sciences companies.
He was co-founder, director and CEO of Leonard Meron Biosciences,
Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of
Roche Laboratories, Inc. ("Roche"), a major research-based
pharmaceutical company, from December
1998 to August 2001. As President of Roche, Mr.
Holubiak helped transform Roche Labs into a leading antibiotic and
biotechnology company. He was also founder of Emron, Inc., a health
economics and managed care consulting company, and helped to create
the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also
a director of Bioscrip, Inc., a national home infusion company,
from 2002 through 2016, and served as its Chairman of the Board
from 2012 through 2016. Since July
2010, Mr. Holubiak has served as a member of the Board of
Directors of Assembly Biosciences, Inc. ("Assembly") and its
predecessor, Ventrus Biosciences, Inc. Mr. Holubiak was also a
trustee of the Academy of Managed Care Pharmacy Foundation. He
received a BS in Molecular Biology and Biophysics from the
University of Pittsburgh; he received
advanced business training from the Harvard
Business School and the University of London, as well as advanced training in health
economics from the University of York's Centre
for Health Economics.
Ms. Petallides joined TD Ameritrade Network in December 2018 as a host based in New York City. Petallides was with FOX
Business Network (FBN) where she anchored Fox Business Morning
(2007) and FBN:AM (2016). For over a decade, she was the New York
Stock Exchange (NYSE) floor correspondent appearing on Fox Business
Network, Fox News Channel, Sky News and the syndicated program Top
30. Prior to joining FBN, she was an anchor at Bloomberg
Television.
About the TD Ameritrade Network
The TD Ameritrade Network is a direct-to-consumer,
broadband-delivered broadcast channel distributing original, live
news broadcasts and educational content produced by TD Ameritrade
Media Productions Company, a wholly-owned subsidiary of TD
Ameritrade Holding Corporation and affiliate of the broker-dealers,
investment advisers, and other regulated financial businesses of
the TD Ameritrade Holding Corporation. TD Ameritrade Media
Productions Company is not a financial adviser, registered
investment adviser, or broker-dealer.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated
to the development and commercialization of critical care products,
with a focus on anti-infectives and cancer care. For more
information, please visit www.citiuspharma.com.
About iMSC
The mesenchymal stem cell therapy product that Citius is pursuing
for in-licensing from Novellus, Inc. is derived from a human
induced pluripotent stem cell (iPSC) line generated using a
proprietary mRNA-based (non-viral) reprogramming process. The
iMSCs produced from this clonal technique are differentiated
from adult donor-derived MSCs (bone marrow, placenta, umbilical
cord, adipose tissue, or dental pulp) by providing genetic
homogeneity. In in-vitro studies, iMSCs exhibit superior
potency and high cell viability. The iMSCs secrete
immunomodulatory proteins that may reduce or prevent pulmonary
symptoms associated with acute respiratory distress syndrome (ARDS)
in patients with COVID-19. The Citius iMSC is an allogeneic
(unrelated donor) mesenchymal stem-cell product manufactured by
expanding material from a master cell bank.
About Acute Respiratory Distress Syndrome (ARDS)
ARDS is a type of respiratory failure characterized by rapid onset
of widespread inflammation in the lungs. ARDS is a rapidly
progressive disease that occurs in critically ill patients – most
notably now in those diagnosed with COVID-19. ARDS affects
approximately 200,000 patients per year in the U.S., exclusive of
the current COVID-19 pandemic, and has a 30% to 50% mortality rate.
ARDS is sometimes initially diagnosed as pneumonia or pulmonary
edema (fluid in the lungs from heart disease). Symptoms of ARDS
include shortness of breath, rapid breathing and heart rate, chest
pain (particularly while inhaling), and bluish skin coloration.
Among those who survive ARDS, a decreased quality of life is
relatively common.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: the risk of successfully
negotiating a license agreement for a potential ARDS therapy with
Novellus, Inc. within the option period; the ability to access the
FDA's CTAP program for our planned ARDS therapy; risks associated
with developing our product candidates, including any licensed from
Novellus, Inc., including that preclinical results may not be
predictive of clinical results and our ability to file an IND for
such candidates; our need for substantial additional funds; risks
associated with conducting our Phase 3 trial for Mino-Lok,
including completing patient enrollment, opening study sites and
achieving the required number of catheter failure events; the
estimated markets for our product candidates, including those for
ARDS, and the acceptance thereof by any market; risks related to
our growth strategy; our ability to identify, acquire, close and
integrate product candidates and companies successfully and on a
timely basis; risks relating to the results of research and
development activities; uncertainties relating to preclinical and
clinical testing; the early stage of products under development;
our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; our ability to attract,
integrate, and retain key personnel; government regulation; patent
and intellectual property matters; competition; as well as other
risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-ceo-myron-holubiak-to-appear-on-td-ameritrade-networks-the-watch-list-with-nicole-petallides-301084872.html
SOURCE Citius Pharmaceuticals, Inc.